Respiratory Disease Testing Market Size & Share 2023 to 2032

Respiratory Disease Testing Market Size

Respiratory Disease Testing Market size was worth USD 14 billion in 2022 and is anticipated to exhibit 6.5% CAGR from 2023-2032. Rising burden of pulmonary and hospital-acquired infections is likely to favor market dynamics.
 

The growing number of government-led initiatives, specifically in the developed and developing regions will complement the market expansion. Several government bodies are coming up with awareness programs for educating the mass population about various respiratory disorders and their prevention.  To illustrate, the National Heart, Lung, and Blood Institute introduced the COPD Learn More Breathe Better (LMBB) campaign for instigating higher awareness along with educating the public regarding COPD (chronic obstructive pulmonary diseases). The campaign is also directed at offering early detection and treatment to individuals affected by various lung diseases.

Higher costs of respiratory disease testing devices to impede industry progress

The escalating costs associated with respiratory disease testing devices may negatively influence the respiratory disease testing market development. To that end, the increasing number of geriatric individuals prone to chronic respiratory infections in some developing countries are refraining from deploying these diagnostic techniques. The presence of financial constraints especially in the economically backward countries and lower-income groups will further hamper the business landscape.
 

Respiratory Disease Testing Market Analysis

Based on test type, the respiratory disease testing market size from in vitro diagnostics tests is anticipated to showcase more than 6% CAGR from 2023-2032. In vitro diagnostics (IVD) respiratory tests or laboratory-based tests are extensively adopted as they render multiple advantages for the diagnosis and treatment of respiratory conditions. Some of these include delivering both non-invasive as well as customizable accurate and rapid results, while ensuring that healthcare providers are offering effective, affordable and personalized care. IVD respiratory tests also help to analyse the samples of bodily fluids, including blood, sputum, or urine for detecting and diagnosing the respiratory conditions.
 

Respiratory disease testing market share from the hospitals end-use segment will exceed USD 10 billion by 2032 due to the strong availability of advanced medical equipment and treatment options. Hospitals are increasingly favoured by patients as they offer better interaction of healthcare professionals on account of ease of accessibility. The growing influx of technologically advanced devices to treat the rising respiratory ailments across the hospital settings in the developed as well as developing countries will anchor the market development.  

North America respiratory disease testing market size is anticipated to strike 6.4% CAGR from 2023-2032. The growth can be attributed to the presence of well-developed healthcare infrastructure in the region. The robust presence of a large number of business players has spurred the introduction of diverse product offerings. The rising burden of respiratory diseases will further anchor the product adoption. As per CDC (Centers for Disease Control and Prevention), nearly 4.6% of adults were diagnosed with emphysema, COPD, or chronic bronchitis in the U.S. in 2021.
 

Respiratory Disease Testing Market Share

Some of the leading players in the respiratory disease testing market include:

• Abbott
• Becton
• Dickinson and Company
• Koninklijke Philips N.V
• ResMed
• VYAIRE MEDICAL INC
• Fischer & Paykel, Medtronic
• BioMerieux SA
• CAREstream Medical Ltd
• Thermo Fischer Scientific
• Cosmed
• Seegene Inc
• SDI Diagnostics
• Siemens Healthineers.
   

The respiratory disease testing market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

By Test Type

• Mechanical Tests
  • Spirometry
  • Peak-flow Test
  • Pulmonary Function Test
  • Blood Gas Test
  • Others
• Imaging Tests
  • X-ray
  • CT-scan
  • Ultrasonography
  • MRI
• In-vitro Diagnostic Tests
  • Point-of-care Test
  • Molecular Diagnostic Test
  • Others

By Application

• Chronic Obstructive Pulmonary Disease
• Lung Cancer
• Asthma
• Tuberculosis Female
• Others

By End-use

• Diagnostic Centers
• Hospitals
• Clinics
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Switzerland
  • Sweden
  • Poland
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Indonesia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Egypt
  • Israel
  • Qatar